<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83958">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01882049</url>
  </required_header>
  <id_info>
    <org_study_id>IDE#G100290</org_study_id>
    <nct_id>NCT01882049</nct_id>
  </id_info>
  <brief_title>Use of Adjustable Gastric Band in Adolescents</brief_title>
  <official_title>Use of the REALIZE™ Adjustable Gastric Band (Model 2200-X) in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the use the adjustable gastric band for the treatment of
      obesity in adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>Monthly up to one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction in percent of excess weight loss (%EWL).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>OBESITY</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gastric band</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>REALIZE (ETHICON)</intervention_name>
    <description>gastric band</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        BMI: Female: ≥ 27 - ≥ 33 Male      ≥ 26 - ≥ 30.5

        Exclusion Criteria:

          -  •Hypertension: Systolic blood pressure (SBP) of 140 mm Hg

               -  Hyperlipidemia:  hyperlipidemia depends on

               -  Obstructive Sleep Apnea:

               -  Metabolic Syndrom: The presence of any three of the following: abdominal obesity
                  - dimensons for children? triglycerides -cholesterol -

          -  fasting glucose

          -  blood pressure

               -  overweight

               -  Non-surgical means of weight reduction failure of

               -  Significant psychopathology (absence of ) that could limit the subject's ability
                  to understand the procedure, comply with medical, surgical, and/or behavioral
                  recommendations, as documented during screening assessment;

               -  Agrees to refrain from any type of reconstructive surgery that would affect body
                  weight such as abdominal lipoplasty or liposuction, mammoplasty, or removal of
                  excess skin for three years following SAGB placement; and

               -  Candidate for surgical weight loss intervention (i.e., meets accepted health
                  criteria for major surgery.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sayeed Ikrammudin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danette Oien</last_name>
    <phone>612 625 8413</phone>
    <email>oienx003@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stanley Williams, PhD</last_name>
    <phone>612 625 3265</phone>
    <email>willi004@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 17, 2013</lastchanged_date>
  <firstreceived_date>November 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
